548 related articles for article (PubMed ID: 33109256)
1. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020).
Huang L; Jiang S; Shi Y
J Hematol Oncol; 2020 Oct; 13(1):143. PubMed ID: 33109256
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the Treatment of Cancer: A Review.
Unnisa A; Chettupalli AK; Hussain T; Kamal MA
Anticancer Agents Med Chem; 2022; 22(20):3370-3381. PubMed ID: 35400324
[TBL] [Abstract][Full Text] [Related]
3. Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
Sakle NS; More SA; Dhawale SA; Mokale SN
Curr Drug Discov Technol; 2020; 17(5):585-615. PubMed ID: 31393251
[TBL] [Abstract][Full Text] [Related]
4. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
Hojjat-Farsangi M
J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367
[TBL] [Abstract][Full Text] [Related]
5. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.
Steeghs N; Nortier JW; Gelderblom H
Ann Surg Oncol; 2007 Feb; 14(2):942-53. PubMed ID: 17103252
[TBL] [Abstract][Full Text] [Related]
6. Receptor tyrosine kinases and targeted cancer therapeutics.
Takeuchi K; Ito F
Biol Pharm Bull; 2011; 34(12):1774-80. PubMed ID: 22130229
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.
Shukla S; Chen ZS; Ambudkar SV
Drug Resist Updat; 2012; 15(1-2):70-80. PubMed ID: 22325423
[TBL] [Abstract][Full Text] [Related]
8. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinases as targets in cancer therapy - successes and failures.
Traxler P
Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
Fang DD; Tao R; Wang G; Li Y; Zhang K; Xu C; Zhai G; Wang Q; Wang J; Tang C; Min P; Xiong D; Chen J; Wang S; Yang D; Zhai Y
BMC Cancer; 2022 Jul; 22(1):752. PubMed ID: 35820889
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.
Gallick GE; Corn PG; Zurita AJ; Lin SH
Future Med Chem; 2012 Jan; 4(1):107-19. PubMed ID: 22168167
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors.
Natoli C; Perrucci B; Perrotti F; Falchi L; Iacobelli S;
Curr Cancer Drug Targets; 2010 Aug; 10(5):462-83. PubMed ID: 20384577
[TBL] [Abstract][Full Text] [Related]
13. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents.
Guo T; Ma S
ChemMedChem; 2021 Feb; 16(4):600-620. PubMed ID: 33179854
[TBL] [Abstract][Full Text] [Related]
15. FGFR-TKI resistance in cancer: current status and perspectives.
Yue S; Li Y; Chen X; Wang J; Li M; Chen Y; Wu D
J Hematol Oncol; 2021 Feb; 14(1):23. PubMed ID: 33568192
[TBL] [Abstract][Full Text] [Related]
16. Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy.
Yin Y; Yuan X; Gao H; Yang Q
Int J Pharm; 2020 Jan; 573():118785. PubMed ID: 31678384
[TBL] [Abstract][Full Text] [Related]
17. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.
Deng J; Shao J; Markowitz JS; An G
Pharm Res; 2014 Sep; 31(9):2237-55. PubMed ID: 24842659
[TBL] [Abstract][Full Text] [Related]
18. Advances in studies of tyrosine kinase inhibitors and their acquired resistance.
Jiao Q; Bi L; Ren Y; Song S; Wang Q; Wang YS
Mol Cancer; 2018 Feb; 17(1):36. PubMed ID: 29455664
[TBL] [Abstract][Full Text] [Related]
19. Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis.
Kim M; Baek M; Kim DJ
Curr Pharm Des; 2017 Nov; 23(29):4226-4246. PubMed ID: 28625132
[TBL] [Abstract][Full Text] [Related]
20. Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
Frampton JE
Drugs; 2021 Apr; 81(6):697-708. PubMed ID: 33871816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]